EXCLUSIVE: Jonathan Hunt On Q2 Numbers, Pharma Sector And Growth Plans For FY25

Syngene International, a Biocon subsidiary, reported an 8.93% year-on-year decline in profit after tax (PAT) for Q2 FY25, with revenue from operations down by 2% year-on-year. Consolidated PAT for the quarter stood at ₹106 crore, while revenue came in at ₹891 crore. However, on a sequential basis, revenue grew by 12.83%, and PAT saw a significant increase of 40.19%. The company’s EBITDA dropped 5% year-on-year. For H1 FY25, revenue from operations was ₹1,681 crore (-2% YoY), with an operating EBITDA margin of 25% (down from 27% in H1 FY24). PAT before exceptional items fell by 25% year-on-year to ₹161 crore, while PAT after exceptional items declined by 13% to ₹182 crore. In an exclusive interview with Business Today TV, Jonathan Hunt, MD & CEO of Syngene International, discusses the company's Q2 performance and shares insights into their plans for FY25. Watch this insightful interview for more details.